Rachna Khosla Sells 2,000 Shares of Amgen (NASDAQ:AMGN) Stock

Amgen Inc. (NASDAQ:AMGN) SVP Rachna Khosla sold 2,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $412.57, for a total transaction of $825,140.00. Following the sale, the senior vice president directly owned 6,404 shares in the company, valued at approximately $2,642,098.28. This represents a 23.80% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Rachna Khosla also recently made the following trade(s):

• On Thursday, August 13th, Rachna Khosla sold 1,252 shares of Amgen stock. The shares were sold at an average price of $416.43, for a total transaction of $521,370.36.

Amgen Trading Down 0.6%

NASDAQ AMGN opened at $415.21 on Friday. Amgen Inc. has a 12-month low of $269.77 and a 12-month high of $421.79. The company has a fifty day simple moving average of $370.57 and a two-hundred day simple moving average of $358.93. The company has a current ratio of 1.37, a quick ratio of 1.13 and a debt-to-equity ratio of 4.44. The stock has a market cap of $224.47 billion, a P/E ratio of 25.81, a P/E/G ratio of 3.88 and a beta of 0.41.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 earnings per share for the quarter, beating analysts’ consensus estimates of $5.62 by $0.67. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The firm had revenue of $10.05 billion for the quarter, compared to analyst estimates of $9.43 billion. During the same period in the previous year, the company earned $6.02 earnings per share. The business’s quarterly revenue was up 9.5% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. On average, analysts forecast that Amgen Inc. will post 22.78 earnings per share for the current year.

Amgen Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, September 11th. Shareholders of record on Friday, August 21st will be given a dividend of $2.52 per share. The ex-dividend date of this dividend is Friday, August 21st. This represents a $10.08 dividend on an annualized basis and a yield of 2.4%. Amgen’s payout ratio is currently 62.65%.

Hedge Funds Weigh In On Amgen

A number of institutional investors have recently modified their holdings of AMGN. Dogwood Wealth Management LLC boosted its stake in shares of Amgen by 275.0% in the fourth quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock worth $25,000 after buying an additional 55 shares during the last quarter. Anfield Capital Management LLC raised its position in Amgen by 1,000.0% during the fourth quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 70 shares in the last quarter. Tower View Wealth Management LLC raised its position in Amgen by 331.6% during the first quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 63 shares in the last quarter. Manning & Napier Advisors LLC lifted its holdings in Amgen by 49.2% in the fourth quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock valued at $32,000 after acquiring an additional 32 shares during the period. Finally, Ares Financial Consulting LLC acquired a new position in Amgen in the fourth quarter valued at approximately $34,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Analyst Upgrades and Downgrades

AMGN has been the topic of a number of research reports. Piper Sandler reissued an “overweight” rating on shares of Amgen in a report on Friday, June 12th. Morgan Stanley lifted their target price on Amgen from $333.00 to $351.00 and gave the stock an “equal weight” rating in a report on Wednesday, August 5th. Barclays upped their target price on Amgen from $360.00 to $380.00 and gave the company an “equal weight” rating in a research report on Friday. TD Cowen raised their price target on shares of Amgen from $420.00 to $452.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Finally, Argus decreased their price objective on shares of Amgen from $400.00 to $375.00 and set a “buy” rating for the company in a research note on Wednesday, May 20th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, fifteen have issued a Hold rating and three have given a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $372.39.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.